Atea Pharma Q2 net loss $28.2M; progresses COVID-19 & HCV trials

Atea Pharmaceuticals, Inc.

2023-Q2 EPS reported -$0.76

Net loss of $28.2M in Q2 2023 (EPS -$0.34) compared to $31.3M loss in Q2 2022.
Cash, equivalents and marketable securities $608.1M, down $38.6M from Dec 2022.
Phase 3 SUNRISE-3 trial amended: eligibility broadened, target enrollment ~2,200; topline expected mid-2024.
Phase 2 HCV study of bemnifosbuvir+ruzavir dosing; initial data from lead-in cohort (~60 pts) expected 4Q23.
R&D expenses rose to $22.1M from $19.9M YoY, driven by trial costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atea Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the three months ended June 30, 2023 and other matters described in the press release.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-206247

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.